letter from the U.S. Food and Drug Administration (FDA) for pitolisant for the treatment of excessive daytime sleepiness (EDS) in adult patients with idiopathic hypersomnia (IH). Harmony’s 2025 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback